Sanofi and Regeneron Pharmaceuticals have announced positive results from the phase 3 CAFÉ study of Dupixent (dupilumab) in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results